Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study

This publication has 18 references indexed in Scilit:

• Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
  Annals of the Rheumatic Diseases, 2017
• Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
  Annals of the Rheumatic Diseases, 2017
• Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
  The Lancet, 2017
• Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
  Drug Metabolism Letters, 2016
• Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
  Clinical Pharmacokinetics, 2015
• Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
  The Journal of Immunology, 2013
• A rapid, accurate and robust UHPLC–MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies
  Journal of Pharmaceutical and Biomedical Analysis, 2013
• Janus kinase inhibitors in autoimmune diseases
  Annals of the Rheumatic Diseases, 2013
• Validation of high-performance liquid chromatography methods for pharmaceutical analysis
  Journal of Chromatography A, 2003
• Signaling by Type I and II cytokine receptors: ten years after
  Current Opinion in Immunology, 2001